Opthalmology Insight Report
Ophthalmologist perspectives on where retinal AI adds value, where algorithms fail, and why trust still depends on image quality, explainability, workflow integration, and who remains accountable for the final decision.
Audience:
Countries:
Survey records:
-Hero findings
– Quick Read — Key Findings
Explore how ophthalmologists are weighing clinical utility, disagreement, automation bias, workflow friction, explainability, and accountability.
Ophthalmology has unusually rich imaging data, making retinal care a natural testing ground for clinical AI. Algorithms can segment OCT layers, quantify fluid, prioritize scans, and support autonomous diabetic retinopathy screening. But the moment an output enters a clinical workflow, the question changes from “Can the model detect it?” to “What happens when the model and the clinician do not agree?”
The FDA classifies diabetic retinopathy detection software as retinal diagnostic software devices that analyze fundus images using adaptive algorithms. Regulatory clearance establishes a pathway for device use, but it does not remove the need for local workflow design, image-quality control, or clinical interpretation around findings that fall outside the system’s intended target.
The survey captures that transition. Ophthalmologists see concrete value in image analysis, particularly OCT segmentation, yet adoption remains uneven and trust is conditional. The responses show that when uncertainty rises, clinicians add information rather than simply choosing human or machine. Alternative imaging, explainability, manual review, and accountability all become part of the decision.
Clinical context: US FDA, Retinal Diagnostic Software Device Classification
The survey includes professionals from United States, United Kingdom, Italy, France, Germany.
MDForLives Research Interpretation
Advanced OCT segmentation leads by a wide margin at 56.8%, while predictive analytics is selected by only 2.7%.
What the pattern suggests: Ophthalmologists favor AI where it can augment a familiar imaging task with quantification, rather than where it asks them to act on a forecast about a future event.
What may be behind it: Layer segmentation, fluid measurement, and atrophy tracking produce visible outputs that can be checked against the raw scan, while prediction requires a different level of confidence in model generalization.
Why it matters: The pattern suggests that explainable augmentation may be reaching routine utility faster than autonomous prediction.
Nearly six in ten order advanced alternative imaging when the AI and clinician disagree, rather than simply choosing one interpretation.
What the pattern suggests: Disagreement is being managed as an uncertainty problem. The dominant response is to generate additional evidence.
What may be behind it: Retinal imaging offers multiple complementary modalities, so OCT-A, fluorescein angiography, or other imaging can help resolve whether the discrepancy reflects missed pathology, image artifact, or model limitation.
Why it matters: The finding complicates the idea that AI either replaces or is ignored by clinicians. In practice, it can become one signal inside a broader diagnostic escalation pathway.
Concomitant multi-pathology leads at 41.7%, followed by media opacity or imaging artifact at 30.6%.
What the pattern suggests: The algorithm appears most vulnerable when the eye does not resemble a clean single-disease example. Complexity in the patient becomes complexity in the image.
What may be behind it: Severe myopia, membranes, diabetic changes, cataract, haze, and anatomical variation can alter features that models rely on, especially when training data underrepresent overlapping conditions.
Why it matters: Real-world robustness depends on more than average accuracy. It depends on how the system behaves in the messy scans clinicians see every day.
Missed incidental pathology leads at 33.3%, closely followed by concern that false positives will flood specialist clinics at 30.6%.
The signing clinician and healthcare organization together account for 71.4% of responses, while only 8.6% place primary responsibility on the developer alone.
What the pattern suggests: Even in an AI-enabled workflow, respondents locate responsibility mainly where the software is selected, deployed, interpreted, and signed off.
What may be behind it: Clinical decisions occur inside organizational systems. The model can generate an output, but clinicians and institutions still control how it enters the chart, how disagreements are handled, and what escalation occurs.
Why it matters: Liability expectations can influence adoption behavior because the person or organization carrying the risk may demand more oversight than the technology technically requires.
A combined 68.6% consider heatmaps, confidence information, or lesion annotations either mandatory or useful reassurance.
What the pattern suggests: Trust is being built through inspectability rather than statistical performance alone, especially in borderline cases.
What may be behind it: Visual explanations give clinicians a way to compare the model’s attention with the raw anatomy and their own interpretation, making disagreement easier to interrogate.
Why it matters: For clinical AI, the ability to show why an output was generated can affect whether the model is usable in practice, even when headline sensitivity and specificity are strong.
OCT segmentation leads current utility and explainability matters to most respondents. The hidden pattern is that clinicians appear more comfortable with augmentation they can visually verify than with opaque prediction.
Most ophthalmologists order alternative imaging when the algorithm and their interpretation diverge. The pattern suggests that AI is becoming another diagnostic signal rather than the final arbiter.
Accountability is placed mainly on clinicians and organizations, while integration friction remains a major barrier. Trust in the software therefore cannot be separated from who carries risk and how the tool fits into the clinical system.
The survey shows genuine clinical value for AI, particularly in advanced OCT segmentation, but it also shows why adoption is uneven. Real-world scans contain artifacts, overlapping disease, and anatomical variation. When AI and human interpretation conflict, most respondents seek additional evidence rather than accepting either answer automatically.
The broader pattern is one of supervised augmentation. Explainability supports trust, accountability remains human and institutional, and workflow integration matters almost as much as technical performance. The future of retinal AI in this cohort looks less like a sudden handover of diagnosis and more like a gradual negotiation over which tasks can be automated without weakening clinical oversight.
You have read the summary
Direct answers to the questions healthcare professionals are most likely to ask about these findings.
